enVVeno Medical Corporation (NVNO)

NASDAQ: NVNO · IEX Real-Time Price · USD
6.01
+0.21 (3.62%)
Aug 17, 2022 3:47 PM EDT - Market closed
3.62%
Market Cap 56.91M
Revenue (ttm) n/a
Net Income (ttm) -23.77M
Shares Out 9.47M
EPS (ttm) -1.90
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 17,380
Open 5.88
Previous Close 5.80
Day's Range 5.74 - 6.18
52-Week Range 3.35 - 11.38
Beta 1.52
Analysts Buy
Price Target 24.48 (+307.3%)
Earnings Date Aug 10, 2022

About NVNO

enVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed i... [Read more...]

Industry Medical Devices
Founded 1987
Employees 24
Stock Exchange NASDAQ
Ticker Symbol NVNO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for NVNO stock is "Buy." The 12-month stock price forecast is 24.48, which is an increase of 307.32% from the latest price.

Price Target
$24.48
(307.32% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Hancock Jaffe to Participate in the Duologue Series Virtual Webinar Hosted by Ladenburg Thalmann

Live webinar followed by Q&A on Monday, September 27th at 1:00 PM ET with Robert Berman Chief Executive Officer of Hancock Jaffe Laboratories IRVINE, CA / ACCESSWIRE / September 24, 2021 / Hancock Jaffe...

Hancock Jaffe To Rebrand As enVVeno Medical

Hancock Jaffe Laboratories Inc (NASDAQ: HJLI) will change its name to enVVeno Medical Corporation and start under a new ticker, "NVNO," from October 1. The Company will also narrow its strategic focus t...

Hancock Jaffe Announces Corporate Rebranding to Reflect Prioritization of its Development Pipeline on Venous Disease ...

- Hancock Jaffe changing name to enVVeno Medical Corporation and ticker symbol to NASDAQ: NVNO, effective October 1, 2021 - - Development strategy to focus on venous disease and advancement of the VenoV...

Hancock Jaffe to Host Corporate Update Conference Call and Webcast on September 21, 2021

Conference call with live video webcast to be held on Tuesday, September 21st at 4:30 p.m. ET IRVINE, CA / ACCESSWIRE / September 15, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaff...

Hancock Jaffe Laboratories Announces $20 Million Registered Direct Offering Priced At-the-Market Under NASDAQ Rules

IRVINE, CA / ACCESSWIRE / September 7, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has entered...

Hancock Jaffe Highlights Two-Year Data For Venous Insufficiency Valve

Hancock Jaffe Laboratories Inc (NASDAQ: HJLI) announced two-year data post-VenoValve implantation in eight patients. Data will be presented at the Society for Vascular Surgery (SVS) Annual Meeting.

Hancock Jaffe Presents New Positive Two-Year VenoValve Data at the Society for Vascular Surgery Annual Meeting

Two-year VenoValve® data shows average improvements in reflux, disease manifestations and pain, of 63%, 60%, and 93%, respectively Patients with venous ulcers who experienced dramatic ulcer healing had ...

Hancock Jaffe Stock Surges On FDA Breakthrough Designation For Its Venous Insufficiency Device

The FDA has granted Breakthrough Device Designation status to  Hancock Jaffe Laboratories Inc's (NASDAQ:HJLI) VenoValve, the Company's lead product, currently set to begin its U.S. pivotal trial.  The V...

FDA Grants Breakthrough Device Designation Status for Hancock Jaffe's VenoValve

- Goal of FDA Breakthrough Device Program is to speed up development by giving priority to devices that treat life-threatening or irreversibly debilitating conditions - Company preparing to begin SAVVE ...

Hancock Jaffe to Present at the Ladenburg Thalmann 2021 Healthcare Conference

Live webcast on Tuesday, July 13th at 1:00 PM ET IRVINE, CA / ACCESSWIRE / July 8, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the "Company"), a developer of medical device...

Hancock Jaffe Principal Investigator Dr. Jorge Hernando Ulloa Presents VenoValve One Year First-In-Human Data at Char...

IRVINE, CA / ACCESSWIRE /  April 23, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that Dr. Jorge Hernan...

First U.S. Patent Issues on Hancock Jaffe VenoValve

IRVINE, CA / ACCESSWIRE / April 7, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the United States ...

Hancock Jaffe Receives IDE Approval To Begin VenoValve U.S. Pivotal Trial

IRVINE, CA / ACCESSWIRE / April 5, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the U.S. Food and ...

Hancock Jaffe Submits IDE Application to FDA for VenoValve U.S. Pivotal Trial

IRVINE, CA / ACCESSWIRE / March 8, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has submitted a...

Hancock Jaffe Concludes Successful VenoValve Pre-IDE Meeting with FDA

Company to Move Forward with Application for VenoValve U.S. Pivotal Trial IRVINE, CA / ACCESSWIRE / January 12, 2021 /  Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices tha...

Hancock Jaffe Announces Executive Promotions

IRVINE, CA / ACCESSWIRE / December 30, 2020  / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that Dr. Hamed Ala...

Hancock Jaffe Deemed Compliant With All NASDAQ Continued Listing Requirements

Company Regains Compliance with NASDAQ Minimum Bid Requirement IRVINE, CA / ACCESSWIRE / December 21, 2020  / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore ...